Sugi Predict

Sugi Predict / Compounds / Butylbenzyl

Butylbenzyl

Butylbenzyl

SCHEMBL2342999

CCCCc1ccccc1.O=S(=O)(Cl)Cl

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 2/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ CNR2 P34972 1/20 0.53
▸ POLB P06746 1/20 0.52
▸ HPGD P15428 2/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ KCNH2 Q12809 2/20 0.49
▸ SIGMAR1 Q99720 1/20 0.48
▸ TRPV1 Q8NER1 1/20 0.47
▸ CHRM2 P08172 1/20 0.47
▸ HTR1A P08908 1/20 0.47
▸ ADRA2A P08913 1/20 0.47
▸ CHRM1 P11229 1/20 0.47
▸ DRD1 P21728 1/20 0.47
▸ SLC6A2 P23975 1/20 0.47
▸ SLC6A4 P31645 1/20 0.47
▸ ADRA1A P35348 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27510222 0.94 MEN1 (0.56) CA2MEN1KMT2ACNR2POLB
SCHEMBL29078912 0.92 KCNH2 (0.59) CA2MEN1KMT2AALDH1A1HSD17B10
SCHEMBL9540326 0.92 KCNH2 (0.59) CA2MEN1KMT2AALDH1A1HSD17B10
SCHEMBL8949509 0.92 KCNH2 (0.59) CA2MEN1KMT2AALDH1A1HSD17B10
SCHEMBL9578506 0.92 KCNH2 (0.59) CA2MEN1KMT2AALDH1A1HSD17B10
SCHEMBL29078911 0.92 KCNH2 (0.59) CA2MEN1KMT2AALDH1A1HSD17B10
SCHEMBL11412978 0.92 KCNH2 (0.59) CA2MEN1KMT2AALDH1A1HSD17B10
Butylbenzyl SCHEMBL27549295 0.88 CA2 (0.63) CA2SMN1; SMN2MEN1KMT2ACNR2
SCHEMBL2342977 0.87 CA2 (0.50) CA2MEN1KMT2ACNR2POLB
Butylbenzyl SCHEMBL16051 0.87 SIGMAR1 (0.59) MEN1KMT2AHPGDALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108191746-A A kind of novel hydroxyl pyridine compounds and preparation method and application 暨南大学 2018-06-22 — — CN claimed
CN-103265436-A Method for synthesising 1,5,9-trinitro-2,3,6,7,10,11-hexa-alkoxy triphenylene UNIV SHAANXI NORMAL 2013-08-28 — — CN claimed
CN-119490439-A Preparation method of arylsulfonyl amino quaternary ammonium salt antibacterial agent 苏州华道生物药业股份有限公司 2025-02-21 — — CN disclosed
CN-110317137-B 9, 10-anthraquinone compound or pharmaceutically acceptable salt thereof and pharmaceutical application thereof 复旦大学 2022-04-19 — — CN disclosed
CN-104910069-B Anthranilic acid analog derivative, its preparation method and its purposes in medicine 北京科技大学 2018-03-23 — — CN disclosed
CN-107001622-A New polymers, its preparation method and its purposes as cell electrolyte of double (sulfonyl) imines sodium or lithium salts containing grafting CDP创新公司 2017-08-01 — — CN disclosed
CN-105377837-A N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB 2016-03-02 — — CN disclosed
CN-104892466-A Anilinosulfonyl compound synthesis method and use of anilinosulfonyl compound as HIV virus inhibitor USTC UNIV SCIENCE TECH CN 2015-09-09 — — CN disclosed
CN-103265436-B Method for synthesising 1,5,9-trinitro-2,3,6,7,10,11-hexa-alkoxy triphenylene UNIV SHAANXI NORMAL 2015-03-18 — — CN disclosed
CN-103554006-A Use of indole derivatives as nurr-1 activators for the application thereof as a medicament for the treatment of parkinson's disease FOURNIER LAB SA 2014-02-05 — — CN disclosed
EP-1648867-B1 PPAR ACTIVE COMPOUNDS PLEXXIKON INC (US) 2013-09-04 — — EP disclosed
EP-1301482-A1 CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS Wyeth (US) 2003-04-16 — — EP disclosed
US-6525202-B2 E.g., substituted (4-amino-5-hydroxyphenyl)-oxy-)piperidinyl thiazolidin-2,4-dione; antidiabetic agents; atherosclerosis, gastrointestinal, metabolic disorders, glaucoma, neurogenetic inflammation, ocular hypertension and frequent urination WYETH 2003-02-25 — — US disclosed
CN-1371376-A substituted purine derivatives as cell adhesion inhibitors AVENTIS PHARMA GMBH (DE) 2002-09-25 — — CN disclosed
US-20020028835-A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists WYETH 2002-03-07 — — US disclosed
WO-2002006232-A1 CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS WYETH (US) 2002-01-24 — — WO disclosed
CN-1281451-A Benzamidine derivatives MERCK PATENT GMBH (DE) 2001-01-24 — — CN disclosed
CN-1272107-A Benzamidine derivatives as factor Xa inhibitors MERCK PATENT GMBH (DE) 2000-11-01 — — CN disclosed
CN-1234039-A 3-mercaptoacetylamino-1, 5-disubstituted-2-oxo-azepane derivatives as matrix metalloproteinase inhibitors HOECHST MARION ROUSSEL INC (US) 1999-11-03 — — CN disclosed
CN-1170405-A Aryl and heteroaryl sulfonamide derivatives, their preparation and their use as endothelin antagonists HOFFMANN LA ROCHE (CH) 1998-01-14 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028835-A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists ADRB1, ADRB3, ADRB2 CA2 3350/4885SMN1; SMN2 3999/4885MEN1 2224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.